Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
replacement
therapies
for
lysosomal
storage
disorders
Agreement is built on a partnership initiated in 2022, supporting continued development led by positive
in
vivo proof-of-concept
data
demonstrating
the
potential
of
Key2Brain's
technology
PARMA, Italy and STOCKHOLM, June 11, 2025 (GLOBE NEWSWIRE) — Chiesi Group and Key2Brain today announced a worldwide license agreement to advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD), including alpha-mannosidosis (aMann) and Krabbe disease (KD), ultra-rare diseases that affect the central nervous system.
The agreement also includes a framework for the parties to include additional enzymes into the collaboration, enabling the expansion of Chiesi's BBB-crossing ERT portfolio and further strengthening its development capabilities. The advancement of these programs will also contribute to Key2Brain's goal of establishing its technology as a leading BBB-crossing platform. At Chiesi Group, these programs are spearheaded by Chiesi Global Rare Diseases, the Group's dedicated business unit focused on research, development, and commercialization of therapies for rare and ultra-rare conditions.
'At Chiesi Global Rare Diseases, we are deeply committed to building a sustainable pipeline in rare diseases by embracing emerging technologies that can enhance the treatment landscape,' said Giacomo Chiesi, Executive Vice President, Chiesi Global Rare Diseases. 'This agreement exemplifies that vision— working to address areas of profound unmet medical need, including neurodegenerative manifestations of ultra-rare diseases like alpha-mannosidosis and Krabbe disease. For too many families, there are still no therapeutic options. Our goal is to bring them hope.'
Under the terms of the agreement, Key2Brain will provide Chiesi Group with a worldwide, royalty- bearing license to develop and commercialize two BBB-crossing ERTs. This agreement is built on an existing research collaboration that aimed to develop the production of a BBB-crossing recombinant alpha-mannosidase. Key2Brain will receive an upfront payment and is eligible to receive development and sales-based milestone payments and tiered royalties on potential sales. Chiesi Group will fund all research, development, and subsequent commercialization worldwide. As part of this agreement, there is also a possibility, upon mutual agreement, for the parties to expand the license to Key2Brain's BBB-crossing technology platform for the development of additional BBB-crossing ERTs.
'This exciting collaboration continuation with Key2Brain represents a strategic opportunity to build on the progress we've already made together,' said Mitch Goldman, Senior Vice President R&D, Chiesi Global Rare Diseases. 'By combining our deep therapeutic expertise with Key2Brain's proprietary BBB-crossing platform technology, we aim to enhance the biodistribution, efficacy and tolerability of promising therapies that have historically faced challenges reaching the central nervous system.
Together, our goal is to unlock new therapeutic pathways for patients with lysosomal storage disorders, ultimately delivering meaningful and lasting innovation.'
Elisabet Sjöström, Ph.D., Founder and CEO, Key2Brain, said, 'Expanding our relationship with Chiesi Global Rare Disease allows us to build on a clinically validated foundation to address the neurological complications of lysosomal storage disorders, including alpha-mannosidosis and Krabbe disease. Through this agreement, we aim to accelerate the research of potential breakthrough therapies that address these neurodegenerative conditions. We believe this partnership serves as a testament to the versatility and competitiveness of our BBB-crossing technology, unique features that are being utilized in Key2Brain's development of our proprietary next-generation brain-targeting therapies.'
This collaboration leverages Key2Brain's proprietary BBB-crossing platform technology and Chiesi Global Rare Diseases' capabilities and expertise in this ultra-rare disease landscape, creating a path to advance the ongoing aMann-K2B program as well as initiate new preclinical programs that apply Key2Brain's technology to other LSDs.
About Chiesi Group
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment.
By changing its legal status to a Benefit Corporation in Italy, the US, France and Colombia, Chiesi's commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For more information visit:
www.chiesi.com
About Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system.
For more information visit:
www.chiesirarediseases.com
. Follow @ChiesiGlobalRareDiseases on
LinkedIn,
Facebook,
Instagram,
X
and
YouTube.
About Key2Brain
Key2Brain is a Swedish biotechnology company dedicated to developing next generation brain targeting therapeutics utilizing its proprietary blood-brain barrier-crossing (BBB-crossing) technology. The technology enables efficient brain uptake and broad distribution of CNS-therapeutics, utilizing small and flexible antibody fragments (VHHs). Key2Brain's VHHs can be integrated into a wide range of therapeutic molecules.
The pipeline is being developed internally and in partnerships where Key2Brain's team leverages extensive industry experience in biologics and brain-targeting drugs, accelerating the translation from discovery to the clinic. Key2Brain was founded 2020 and is based in Stockholm.
For more information visit:
www.key2brain.com
About Key2Brain's technology platform
Key2Brain's technology enables efficient brain uptake and broad distribution of therapeutics, utilizing small (<15kDa) engineered single domain VHH antibodies with monovalent specificity for the Transferrin Receptor (TfR). The technology provides opportunities for the development of next generation brain targeting across a diverse range of therapeutic areas.
Key2Brain's VHH technology can be efficiently integrated into or combined with therapeutic molecules without impacting either the disease target specificity, or the binding of transferrin to TfR. The modular and flexible platform is being applied to peptides, proteins, enzymes, and oligonucleotides.
Key2Brain's VHHs can be expressed in both prokaryotic and eukaryotic systems and purified using commercial large-scale affinity purification systems. The proprietary platform includes species cross-reactive (human/primate/mouse) as well as human/primate specific binders together with a humanized TfR mouse model for translational studies.
Chiesi Global Rare Diseases Media Contact
Sky Striar
LifeSci
Communications
sstriar@lifescicomms.com
Key2Brain Media Contact
Benjamin Nordin, CBO
Key2Brain
benjamin.nordin@key2brain.se
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
a day ago
- New York Post
Biohacker's 4 crucial steps to therapy with psychedelics — and a non-drug technique to try first
Dave Asprey's psychedelic journey spans continents and states of consciousness — from microdosing LSD in LA to sipping Ayahuasca with shamans in the mountains of Peru. The self-proclaimed 'father of biohacking' has long touted the potential brain-boosting, trauma-releasing and even life-extending power of these mind-bending substances. But it's not all bliss and breakthroughs. In his new book 'Heavily Meditated,' Asprey warns that psychedelics carry real risks and stresses that proper preparation is key to avoiding a trip gone wrong. 5 Dave Asprey shares his psychedelic experiences in his new book, 'Heavily Meditated: The Fast Path to Remove Your Triggers, Dissolve Stress, and Activate Inner Peace.' Getty Images 'It can take months to heal psychologically if you have a bad reaction or if you choose to try it alone without the support of an expert,' he wrote, noting that a 'meaningful number of people have mental breaks afterward.' So, how do you trip smarter — not harder? Asprey outlined four key steps to prepare for a psychedelic experience that can help maximize benefits and minimize risks. But before you reach for the drugs, he wants you to try this first. 'You can access the same altered states with other methods outside of these substances, like holotropic breathwork,' Asprey told The Post. This technique combines rapid, controlled breathing with sensory music to promote mental, spiritual and physical healing. Asprey interviewed the creator of holotropic breathwork, Dr. Stanislav Grof, on his podcast, 'The Human Upgrade.' Grof explained that the technique slows oxygen flow to the brain, triggering distress signals to the limbic system. This breathing style alters your self-perception and sense of time, inducing a psychedelic state. 5 Studies suggest that one in four Americans have tried at least one psychdelic drug in their lifetime. vlorzor – 'It felt like tripping balls — my mind was on a hyperdrive tour of the universe. But there were no drugs involved,' Asprey wrote about his first experience in 'Heavily Meditated.' This altered state of consciousness is believed to help people access parts of the psyche typically out of reach, allowing them to work through emotional blocks and unresolved issues. 'It dug up stuff deeper than anything I've experienced, even more profound than my trips with ayahuasca,' Asprey noted. While it's generally considered safe, holotropic breathwork isn't recommended for certain groups, such as those with a history of cardiovascular issues, high blood pressure, panic attacks, psychosis or seizure disorders, according to the Cleveland Clinic. Still curious about trying mind-altering substances? Asprey says these four steps are key to a smooth and successful experience. 5 Traditionally, psychedelic substances like ayahuasca are taken under the guidance of an experienced shaman. AFP via Getty Images #1. Set the scene 'Find a very reputable guide and a safe space,' Asprey advised. 'Don't go at it alone.' Psychedelics can stir up a wide range of emotions — including fear, anxiety and confusion — often referred to as a 'bad trip.' Without support, managing those intense feelings can be difficult and overwhelming. 'Some of these experiences can leave marks that aren't easy to shake off.' Dave Asprey Being in a chaotic, stressful or unsafe environment can amplify those reactions, increasing the risk of a negative experience. Across the US, a growing number of states and cities are moving to legalize and regulate therapeutic psychedelic use. That includes Oregon, where licensed clinics can administer psilocybin — the active compound in psychedelic mushrooms — to adults 21 and older under the supervision of trained facilitators. Clinical trials are also underway at institutions like Mount Sinai's Parsons Research Center for Psychedelic Healing, which features dedicated treatment and group therapy rooms designed to support safe, supervised psychedelic therapy and research. #2. Come up with a plan Working with a trained expert can also help you understand how different substances, strains and doses affect the mind and body. 'Start slow,' Asprey recommended. 'Some people can handle more without losing their minds. Others can access altered states with smaller doses.' 5 Psilocybin, the psychedelic compound found in certain mushrooms, is being studied for its potential therapeutic effects. contentdealer – #3. Anchor your experience While many people view psychedelics as purely recreational, Asprey suggests treating the trip as an opportunity for insight, not just pleasure. 'Be clear on your intentions,' he advised. Establishing a purpose beforehand can help guide the experience toward healing or personal growth. It also serves as a mental anchor if things become overwhelming or disorienting, reducing the risk of the journey going off track. 5 There are a wide variety of practices used to integrate a psychedelic experience, including creative expression and quiet meditation. BullRun – #4 Don't neglect your post-trip 'You must integrate afterwards,' Asprey said. 'This is crucial.' Integration means taking time to process the emotions, realizations, or insights that surfaced during a psychedelic experience. It's how you extract long-term value — and avoid letting breakthroughs fade into the background. This might involve journaling, creating art, meditating, joining a support group, or working with a trained therapist. 'I see people getting high every weekend with no integration and no therapeutics,' Asprey said. 'That's not how to do it, especially if you're in your 20s.' 'When used wisely and with respect, psychedelics can provide a profound inner journey that opens doors to uncharted territories of your mind,' Asprey wrote in 'Heavily Meditated.' 'But there's a catch — some of these experiences can leave marks that aren't easy to shake off,' he added. 'That's why environment, mindset and having an experienced guide are crucial if you choose to journey with any of them, especially if you're inexperienced.'
Yahoo
4 days ago
- Yahoo
Trump weighs marijuana reclassification as Oklahoma eyes recreational legalization
President Donald Trump said his administration is weighing whether to reclassify marijuana as a less dangerous drug. This move could mark the most significant federal shift in cannabis policy in half a century. "We're looking at reclassification and we'll make a determination over the next few weeks," Trump said at an Aug. 11 news conference. The federal government lists marijuana alongside heroin and LSD as a Schedule I drug — the category reserved for substances deemed highly dangerous, addictive and without medical value. Reclassifying it to Schedule III, as recommended by federal health officials in 2023, would put marijuana in the same legal tier as Tylenol with codeine and anabolic steroids, allowing it to be prescribed by licensed medical providers and dispensed by pharmacies. It would not, however, legalize recreational use under federal law. What a federal shift could mean for Oklahoma Oklahoma legalized medical marijuana in 2018 and more than 2,000 dispensaries now operate statewide. But under current law, adults can only purchase cannabis with a medical patient license. That could change if voters approve State Question 837, which would legalize recreational sales for adults 21 and older. The measure cleared a major procedural hurdle in July and organizers have already started gathering signatures. Organizers have until Nov. 4 to collect at least 172,993 valid signatures to get on the ballot in 2026. If Trump reclassifies marijuana to Schedule III, Oklahoma's medical marijuana market — already among the largest per capita in the nation — could see smoother banking operations, lower compliance risks for dispensaries and broader medical research opportunities. But the move would do nothing to authorize recreational sales in the state; that decision would still rest entirely with Oklahoma voters. The push for SQ 837 Oklahomans for Responsible Cannabis Action (ORCA), the group behind SQ 837, is betting that public sentiment has shifted since voters rejected a similar measure, State Question 820, in 2023 by a 61% margin. This time, ORCA is pursuing a constitutional amendment, making it harder for lawmakers to alter or repeal the law without another statewide vote. The proposal would tax recreational sales at 10% while preserving the medical system and exempting licensed patients from the new tax. The campaign faces new hurdles, including a 2025 state law limiting how many petition signatures can come from a single county. That means ORCA can't rely solely on the city center like Tulsa or Oklahoma City for signatures and will have to fan out into rural areas — such as Harmon County, where just 117 residents will be allowed to sign. "Maybe we'll go and hang out at the co-op for a day or go to the county courthouse," ORCA Director Jed Green said. "Voters of Harmon County — get ready, we'll come out and visit." Open primary supporters have challenged Senate Bill 1027 in the Oklahoma Supreme Court, which has not yet issued a ruling. The bigger picture Trump's comments come after years of fits and starts on federal marijuana policy. President Joe Biden initiated the reclassification review in 2022, and federal health officials recommended the downgrade in 2023. The Drug Enforcement Administration proposed a rule change in 2024, but the process stalled after Trump returned to the White House in January. Terrance Cole, Trump's newly confirmed DEA administrator, has said reviewing marijuana's classification will be one of his first priorities, though he has not signaled whether he supports the change. Trump said the decision is complicated, weighing the benefits of marijuana use for medical reasons against potential societal impacts. "Some people like it, some people hate it," he said. "Some people hate the whole concept of marijuana." If the administration follows through, Oklahoma's cannabis industry could get a boost in legitimacy and access to services — but recreational marijuana will still live or die by the state's ballot box. This article originally appeared on Bartlesville Examiner-Enterprise: Trump considers marijuana shift; Oklahoma advances recreational use Solve the daily Crossword
Boston Globe
4 days ago
- Boston Globe
What to know about Trump's potential change in federal marijuana policy
What's the federal policy on marijuana? Possessing marijuana remains a federal crime punishable by fines and prison time. Selling or cultivating marijuana is a more serious offense, punishable by prison sentences of five years to life, depending on the quantity of the drug. Advertisement The Justice Department last year proposed to reclassify marijuana from a Schedule I drug, alongside heroin and LSD, to a less dangerous Schedule III substance, which includes such things as ketamine and some anabolic steroids. But that switch involved a lengthy bureaucratic process. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Nearly 43,000 public comments were submitted to the federal government about the proposed change. The Drug Enforcement Administration was still in the review process when Trump succeeded Biden in January, triggering a re-examination of policies across the federal government. What would reclassifying marijuana mean? Reclassifying marijuana would not make it legal for recreational use by adults nationwide. Rather, it would change the way it's regulated and taxed. Federal income tax deductions for business expenses aren't available to enterprises involved in 'trafficking' any Schedule I or II drug. Changing marijuana to a Schedule III drug could mean significant tax savings for businesses licensed to sell marijuana in states where it is legal. Advertisement It also could make it easier to research marijuana, since it's very difficult to conduct authorized clinical studies on Schedule I substances. Due to the potential for federal penalties, many banks and financial institutions don't provide debit or credit services, loans or other common banking products to marijuana businesses authorized under state laws. That's unlikely to change merely by rescheduling marijuana under the federal Controlled Substances Act, according to a Congressional Research Service report. What is there for Trump to consider? Trump is weighing the pros and cons of a marijuana policy change, noting it's a 'very complicated subject.' 'I've heard great things having to do with medical' use of marijuana and 'bad things having to do with just about everything else,' Trump said Monday. Marijuana advocacy groups have long pushed for the federal government to soften its stance. As a candidate, Trump appeared open to relaxed regulation, posting on his social media platform last year that he would 'focus on research to unlock the medical uses of marijuana to a Schedule 3 drug.' But reclassification faces resistance from some conservatives and law enforcement groups. The National Sheriffs' Association was among those submitting written opposition, highlighting prior determinations that marijuana has a 'high abuse potential' and pointing to cases of 'extreme intoxication' and fatal vehicle crashes. What's happening in the states? The medical use of marijuana is already allowed in 40 states and the District of Columbia. Over the past dozen years, the number of jurisdictions legalizing recreational marijuana for adults rose rapidly to 24 states and the District of Columbia. Advertisement But the movement suffered some recent setbacks. Ballot measures to legalize recreational marijuana failed last fall in Florida, North Dakota and South Dakota. Florida's measure received a majority vote, which would have been sufficient in most states, but fell short of the 60% threshold needed to approve amendments to the state constitution. Idaho lawmakers this year referred a proposed constitutional amendment to the ballot that would forbid citizen initiatives to legalize marijuana and instead leave such decisions only to the Legislature. Initiatives continue elsewhere to try to place recreational marijuana on the ballot, including in Oklahoma, where voters defeated a measure in 2023. What does the data say about marijuana use? About 6 in 10 voters across the country said they favor legalizing recreational use nationwide, according to AP VoteCast, a survey of more than 120,000 U.S. voters conducted during last year's election. Polling from Gallup shows support for marijuana legalization has grown significantly, from just 36% support in 2005 to 68% last year. Marijuana use has also increased. More than 64 million Americans age 12 and older — or 22.3% of people — used marijuana during the past year, according to a 2024 national survey released recently by the federal Substance Abuse and Mental Health Services Administration. That was up from 19% of people in 2021. The growth in marijuana use was driven by adults aged 26 and older, according to the survey. However, people ages 18-25 remained the most likely to partake in marijuana, with 35% reporting use during the past year.
